Phospholipid Ester Conjugated Linoleic Acid Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psychiatric disorders with neuroinflammatory and neurodegenerative bases, such as depression and schizophrenia, are inadequate in addressing the underlying neuroinflammatory mechanisms, leading to suboptimal clinical outcomes and unmet clinical needs.
Innovation Solution
The development of a phospholipid ester conjugated with conjugated linoleic acid (CLA), specifically the c9,t11 isomer, which is readily incorporated into the central nervous system, activates PPAR alpha, increasing levels of PEA and OEA, thereby exerting anti-inflammatory effects and promoting neurogenesis, reducing TNF-alpha levels, and improving dopaminergic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for psychiatric disorders, then treatment is provided, but the underlying neuroinflammatory mechanisms are not adequately addressed, leading to suboptimal clinical outcomes
Solution Approach 1:
The patent introduces PPAR alpha as an intermediary target that mediates between the administered compound and the neuroinflammatory pathways. By activating PPAR alpha, the treatment indirectly addresses neuroinflammatory mechanisms through this molecular mediator, thereby improving clinical outcomes while specifically targeting the harmful inflammatory pathways in psychiatric disorders
Solution Approach 2:
The patent employs parameter changes by modifying the metabolic state through PPAR alpha activation, which alters the expression of genes involved in inflammation and metabolism. This changes the biochemical parameters of neuroinflammatory pathways, shifting them from a pro-inflammatory state to an anti-inflammatory state, thus addressing the underlying mechanisms while improving treatment reliability
2Object-affected harmful factors
If anti-inflammatory treatments are applied, then neuroinflammatory activation is reduced, but the complexity of treating multiple psychiatric symptoms simultaneously increases
Solution Approach 1:
The patent applies universality by using a single compound that simultaneously addresses multiple aspects of psychiatric disorders through PPAR alpha activation. This multi-functional approach tackles neuroinflammatory activation, metabolic abnormalities, and neuronal protection in one treatment, reducing overall treatment complexity while effectively reducing neuroinflammatory activation across different psychiatric conditions
3Ease of operation
If current antidepressant therapies are used, then depressive symptoms are treated, but neurogenesis and neuronal plasticity effects are insufficient
Solution Approach 1:
The patent uses parameter changes by activating PPAR alpha to alter the biochemical environment in a way that promotes neurogenesis and neuronal plasticity. This changes key parameters such as brain-derived neurotrophic factor expression and synaptic plasticity markers, thereby improving the reliability of neurogenic effects while maintaining ease of operation for treating depressive symptoms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The phospholipid ester with CLA enhances anti-inflammatory responses, improves neuronal function, and shows potential in treating psychiatric disorders by reducing inflammatory mediators and promoting synaptic and neuronal growth, offering a novel therapeutic approach for neuroinflammatory and neurodegenerative conditions.
Implementation Method 1
activates PPAR alpha, increasing levels of PEA and OEA, thereby exerting anti-inflammatory effects
Implementation Method 2
reducing TNF-alpha levels, and improving dopaminergic function
Data Source
Figure 1A~1B
Figure 2~3
AI summary
The present invention relates to an ester of a phospholipid with conjugated linoleic acid for use in the therapeutic treatment of or as a food supplement for psychiatric disorders with neuroinflammatory and neurodegenerative basis, such as depression and schizophrenia.